{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-22-000043","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.517719+00:00","generated_at":"2026-06-27T03:32:53.990412+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Castle Biosciences FY2021 revenue $94.1M (+50% YoY); guides FY2022 $115-120M","bullets":["Full-year 2021 revenue $94.1M, up 50% vs $62.6M in 2020; net loss $(31.3)M vs $(10.3)M.","Total GEP test volume 28,118 (+55% YoY); DecisionDx-Melanoma 20,328 (+25%).","Q4 revenue $25.0M (+45% YoY); delivered 8,242 test reports (+60%).","Cash and equivalents $330M at Dec. 31, 2021; adjusted EBITDA $(14.9)M for 2021.","FY2022 revenue expected $115-120M; includes TissueCypher Barrett's esophagus test."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-22-000043","json":"https://secwatch.observer/filing/0001447362-22-000043.json","markdown":"https://secwatch.observer/filing/0001447362-22-000043.md","text":"https://secwatch.observer/filing/0001447362-22-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000043/0001447362-22-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736222000043/cstl-20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:32:53.990412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}